A federal court in Massachusetts reduced Insulet Corporation's $452 million jury award against EOFlow Co., Ltd. to $59.4 million to avoid double recovery, while also granting a permanent injunction and ordering the reassignment of patent applications. The court found that the original damages award overlapped with the injunctive relief sought by Insulet.
The reduced award includes $25.8 million in unjust-enrichment damages for avoided costs and $33.6 million in exemplary damages, capped at twice the unjust-enrichment amount as per the Defend Trade Secrets Act. The court's April 24, 2025, ruling followed a jury verdict that found EOFlow liable for misappropriating four of Insulet's trade secrets, including an occlusion-detection-algorithm.
While the monetary award was significantly reduced from the jury's initial verdict, the court's decision to grant a permanent injunction and order patent reassignment is a critical victory for Insulet. This outcome effectively blocks EOFlow from continuing to use and profit from the stolen technology, protecting Insulet's long-term competitive advantage and intellectual property. The reassignment of patents further solidifies Insulet's technological lead.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.